PRESSRELEASES
29 April, 2026
Nanexa publishes interim report for January-March 2026
Opened the year with strong preclinical results for once-monthly and quarterly dosing of semaglutide
READ MORE28 April, 2026
Nanexa resolves on set-off of outstanding loan
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION, OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. FURTHER RESTRICTIONS APPLY.
READ MORELATEST REPORTS
PRESENTATIONS
29 April 2026
Q1 report commentary with CEO David Westberg
19 February 2026
Q4 report commentary with CEO David Westberg and Chairman of the Board Göran Ando
11 December 2025
Nanexa and Moderna enter into license and option agreements
6 November 2025
Q3 report commentary with CEO David Westberg
MEET NANEXA
18–20 May 2026
Nanexa will participate in DDF Summit 2026 in Berlin, Germany on 18-20 May
Dr. Joel Hellrup serves as Head of Pharmaceutical R&D at Nanexa and will give a talk on 19 May about PharmaShell®: Atomic layer deposition enabling once‑monthly and once‑quarterly semaglutide depots, with clinical proof‑of‑concept from liraglutide.
22–25 June 2026